MBK Partners poised to acquire CJ Cheiljedang’s $3.5 billion bio business

Quick Summary:

CHINA’S TWO LEADING BIOTECH FIRMSLast month, MBK and two leading Chinese biotechnology firms – Guangxin Group and Meihua Group – joined the race for management control of CJ’s bio business in what would be Korea's largest M&A deal this year.

North Asia-focused private equity firm MBK Partners is on the verge of clinching a major acquisition deal, offering a higher bid than other contenders for South Korea’s CJ Cheiljedang Corp.'s bio business – a deal estimated at 5 trillion won ($3.5 billion).

CJ Cheiljedang, the flagship unit of Korea’s food-to-entertainment conglomerate CJ Group, has put up its bio business for sale in line with the parent group’s restructuring efforts to revive sagging sales at its two growth pillars: food and entertainment.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South KoreaBrazilChinaIndonesia

Topics: Korea Partners Homeplus Sale Market Deal Cheiljedang Trillion Sales Business Group

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-03-06 @ 20:35:33 (2 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 574 words

Reading Time: 4 minutes read

Sentences: 30 lines

Sentence Length: 20 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 26694671

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 9 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 5 hours ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions